KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 51,679,622
- Total 13F shares
- 55,190,249
- Share change
- +4,688,343
- Total reported value
- $467,414,520
- Put/Call ratio
- 271%
- Price per share
- $8.47
- Number of holders
- 129
- Value change
- +$30,397,001
- Number of buys
- 69
- Number of sells
- 46
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
12%
|
6,249,731
|
$72,371,885 | — | 30 Sep 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
8.4%
|
4,321,547
|
$50,043,514 | — | 30 Sep 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.2%
|
4,212,005
|
$48,775,018 | — | 30 Sep 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
7.7%
|
4,000,000
|
$46,320,000 | — | 30 Sep 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
7.1%
|
3,687,867
|
$42,705,500 | — | 30 Sep 2024 | |
| Capital World Investors |
13F
|
Company |
6.5%
|
3,374,064
|
$39,071,661 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
5.9%
|
3,062,319
|
$35,461,654 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.2%
|
2,150,527
|
$24,903,102 | — | 30 Sep 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
3.1%
|
1,590,000
|
$18,412,200 | — | 30 Sep 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.7%
|
1,419,792
|
$16,441,191 | — | 30 Sep 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
2.5%
|
1,299,503
|
$15,048,245 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
1,271,609
|
$14,725,232 | — | 30 Sep 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.7%
|
896,915
|
$10,386,276 | — | 30 Sep 2024 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
1.6%
|
835,988
|
$9,680,741 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
830,984
|
$9,624,149 | — | 30 Sep 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.4%
|
723,678
|
$8,380,191 | — | 30 Sep 2024 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1.3%
|
650,980
|
$7,538,348 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
1.2%
|
608,253
|
$7,043,570 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.2%
|
607,036
|
$7,031,452 | — | 30 Sep 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
574,558
|
$6,653,382 | — | 30 Sep 2024 | |
| Saturn V Capital Management LP |
13F
|
Company |
1.1%
|
556,489
|
$6,444,143 | — | 30 Sep 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.83%
|
431,232
|
$5,321,403 | — | 30 Sep 2024 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.73%
|
379,375
|
$4,393,162 | — | 30 Sep 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.73%
|
375,000
|
$4,342,500 | — | 30 Sep 2024 | |
| First Turn Management, LLC |
13F
|
Company |
0.69%
|
355,000
|
$4,110,900 | — | 30 Sep 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.59%
|
305,504
|
$3,537,737 | — | 30 Sep 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.59%
|
303,864
|
$3,518,745 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.58%
|
297,402
|
$3,443,921 | — | 30 Sep 2024 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.35%
|
180,000
|
$2,084,400 | — | 30 Sep 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
178,608
|
$2,068,281 | — | 30 Sep 2024 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.3%
|
154,522
|
$1,789,365 | — | 30 Sep 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.26%
|
135,552
|
$1,569,692 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.26%
|
134,041
|
$1,552,195 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.25%
|
127,249
|
$1,473,543 | — | 30 Sep 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.23%
|
117,923
|
$1,365,548 | — | 30 Sep 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.22%
|
115,992
|
$1,343,191 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
110,720
|
$1,282,138 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
105,611
|
$1,222,976 | — | 30 Sep 2024 | |
| Edward P. Feener |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
102,024
mixed-class rows
|
$1,200,262 | — | 17 May 2024 | |
| Zimmer Partners, LP |
13F
|
Company |
0.19%
|
95,704
|
$1,108,252 | — | 30 Sep 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.17%
|
89,929
|
$1,041,378 | — | 30 Sep 2024 | |
| Birchview Capital, LP |
13F
|
Company |
0.16%
|
82,000
|
$949,560 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.16%
|
80,443
|
$931,530 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.13%
|
67,222
|
$778,431 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0.13%
|
66,423
|
$769,178 | — | 30 Sep 2024 | |
| ClariVest Asset Management LLC |
13F
|
Company |
0.11%
|
57,096
|
$672,591 | — | 30 Sep 2024 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.11%
|
54,468
|
$630,739 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.1%
|
52,694
|
$610,196 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.1%
|
50,279
|
$582,221 | — | 30 Sep 2024 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2024
As of 31 Dec 2024,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,190,249 shares.
The largest 10 holders included
VR Adviser, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, Capital World Investors, BlackRock, Inc., VANGUARD GROUP INC, GREAT POINT PARTNERS LLC, and Boxer Capital Management, LLC.
This page lists
129
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
120
Q4 2024 holders
129
Holder diff
9
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.